Osaka: Takeda has received approval from the European Commission (EC) for ADCETRIS (brentuximab vedotin) in combination with ...

Takeda Pharmaceutical Company Limited (NYSE: TAK )’s ADCETRIS® (brentuximab vedotin) in combination with ECADD was authorized ...

The drug has been approved in combination with the chemotherapy regimen etoposide, cyclophosphamide, doxorubicin, dacarbazine ...

The European Commission (EC) has approved Adcetris (brentuximab vedotin) in combination with etoposide, cyclophosphamide, ...

The European Commission (EC) has approved Takeda's antibody-drug conjugate (ADC) Adcetris (brentuximab vedotin) plus the ...

Takeda (NYSE:TAK) (4502.T) said on Monday that the European Commission approved Pfizer (NYSE:PFE) and the company's ...

Despite recent declines, we believe Pfizer stock is a compelling buy right now, with its current price of around $23 likely ...

Enbrel revenues declined 6% to $140 million. Pfizer’s acquisition of Seagen in December 2023 added antibody-drug conjugates or ADCs — Adcetris, Padcev, Tukysa and Tivdak — to its cancer portfolio.

Takeda has announced a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) recommending European Commission (EC) approval of Adcetris (brentuximab vedotin) in combination ...

Takeda UK has announced that the National Institute for Health and Care Excellence (NICE) has recommended Adcetris (brentuximab vedotin) as part of a combination treatment for adults with untreated ...

Adcetris is also indicated as monotherapy or in combination with chemotherapy for the treatment of certain types of classical Hodgkin lymphoma, anaplastic large cell lymphoma and peripheral T-cell ...

Pfizer Inc. announced that the US Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for Adcetris (brentuximab vedotin) in combination with ...